Aberdeen Group plc Raises Stock Holdings in Humana Inc. $HUM

Key Points

• Aberdeen Group plc increased its stake in Humana Inc. by 4.6%, now holding approximately $34.69 million worth of shares after acquiring more during the first quarter.
• Despite a missed earnings estimate of $6.32 by $0.05, Humana reported quarterly revenue of $32.39 billion, exceeding forecasts.
• The company's stock received mixed ratings from analysts, resulting in a consensus rating of "Hold" and a price target of $281.43.

Aberdeen Group plc raised its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 4.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,669 shares of the insurance provider's stock after acquiring an additional 5,809 shares during the period. Aberdeen Group plc owned about 0.11% of Humana worth $34,693,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of HUM. Revolve Wealth Partners LLC bought a new stake in shares of Humana during the 4th quarter worth $202,000. Mariner LLC raised its stake in shares of Humana by 4.0% during the 4th quarter. Mariner LLC now owns 13,461 shares of the insurance provider's stock worth $3,415,000 after purchasing an additional 517 shares during the period. Insigneo Advisory Services LLC raised its stake in shares of Humana by 17.3% during the 4th quarter. Insigneo Advisory Services LLC now owns 1,360 shares of the insurance provider's stock worth $345,000 after purchasing an additional 201 shares during the period. Forum Financial Management LP raised its stake in shares of Humana by 62.0% during the 4th quarter. Forum Financial Management LP now owns 1,916 shares of the insurance provider's stock worth $486,000 after purchasing an additional 733 shares during the period. Finally, First Trust Advisors LP raised its stake in shares of Humana by 78.6% during the 4th quarter. First Trust Advisors LP now owns 93,328 shares of the insurance provider's stock worth $23,678,000 after purchasing an additional 41,070 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

Humana stock traded up $1.8540 during midday trading on Wednesday, reaching $290.1040. The stock had a trading volume of 1,247,722 shares, compared to its average volume of 1,729,720. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $382.72. The firm's 50-day moving average price is $244.92 and its 200 day moving average price is $253.44. The firm has a market capitalization of $34.89 billion, a PE ratio of 22.26, a P/E/G ratio of 1.69 and a beta of 0.44. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, research analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on HUM shares. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a research note on Thursday, May 1st. Wells Fargo & Company lowered their target price on Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a research note on Thursday, August 14th. Piper Sandler lowered their target price on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research note on Thursday, July 31st. Wall Street Zen cut Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Morgan Stanley lowered their price objective on Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Seven equities research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $281.43.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.